Select therapeutic use:
Indications for HYPERRAB S/D:
Postexposure prophylaxis of rabies.
See literature. Give by IM inj preferably at the time of 1st vaccine dose; may be given through 7th day after 1st vaccine dose is given. 20 IU/kg (0.133mL/kg) once. If feasible, up to full dose should be infiltrated in area around wound and the rest into deltoid muscle of upper arm or lateral thigh muscle.
Previously immunized with rabies vaccine with a confirmed adequate rabies antibody titer: not recommended. Contains human plasma; monitor for possible infection transmission. IgA-deficiency. Thrombocytopenia or other bleeding disorders. Prior history of allergic reactions to human immunoglobulins. Have epinephrine inj available. Pregnancy (Cat.C).
Avoid live vaccines within 3 months.
Inj site reactions, mild temp elevations; rare: angioneurotic edema, rash, nephrotic syndrome, anaphylactic shock.
Single-use vial (2mL, 10mL)—1